Lyric Bio
June 25, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Tools/Drug Development Support Tech
Lyric Bio is expanding biomanufacturing to human donor-derived biologics. Using proprietary tissue-engineering technology and a laser-printed cellular substrate, the company is developing high-density (1-2B cells/mL), tissue-mimicking bioreactors that enable in-vitro production of IVIg from human B cells; currently, 100% of IVIg is sourced from human plasma donations. Lyric's technology has the potential to reduce costs 10-100x, reliance on human donors 10,000-fold, and improve quality of IVIg therapeutics. This is solving a critical need in a $20B supply constrained therapeutic market, and as a result the company has significant traction with current market leaders including a strategic investment, R&D collaboration, and a letter of support. The platform also has the potential to unlock broader applications across biomanufacturing.
Company HQ City:
San Carlos
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2025
CEO
Kayj Shannon
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}